论文部分内容阅读
长期以来,我国一直是一个医药消费大国,同时又远远不是一个医药强国。其主要原因就在于我们的新药研发能力薄弱。自上个世纪八十年代改革开放以来,我国的许多行业如通信、IT业甚至汽车行业借着开放的契机,或通过引入资金,或通过引入技术,均获得了长足的发展,缩小了与世界先进水平的差距。但在医药行业,由于制药工业的极度分散、新药研发机构的经济实力有限,再加上医药行业较之其它行业更为严格的行政管制制度及措施,我国的新药研发能力并没有获得长足的进展。在发达国家对药品的严格的知识产权保护措施及压力下,我国的许多企业及科研机构只能利用国内政策的优势,通过对国外药品的仿制作为自己新药的研发途径。这种方式虽然可以暂时满足医药市场的需求,缓解公民越来越强烈的对健康保障的需求,但却不能从根本上提高国内医药行
For a long time, our country has always been a large pharmaceutical consumer and far from being a medical powerhouse. The main reason is that our new drug research and development capabilities are weak. Since the reform and opening up in the 1980s, many industries in our country, such as communications, IT and even the automotive industry, have made great strides by opening up opportunities or by introducing funds or introducing technologies, narrowing the gap with the world The advanced level of the gap. However, in the pharmaceutical industry, due to the extremely scattered pharmaceutical industry and the limited economic strength of the new drug research and development institutions, coupled with the more stringent administrative regulations and measures in the pharmaceutical industry as compared with other industries, the capability of research and development of new drugs in our country has not made great strides . Under the stringent intellectual property protection measures and pressure on pharmaceuticals in developed countries, many enterprises and research institutes in our country can only take advantage of domestic policies and adopt the imitation of foreign drugs as their new drug research and development path. Although this approach can temporarily meet the needs of the pharmaceutical market and ease the citizens’ increasingly strong demand for health protection, they can not fundamentally improve the domestic pharmaceutical industry